Two patients with Lassa fever are described who are the first human cases treated with a combination of ribavirin and favipiravir. Both patients survived but developed transaminitis and had prolonged detectable virus RNA in blood and semen, suggesting that the possibility of sexual transmission of Lassa virus should be considered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682919 | PMC |
| http://dx.doi.org/10.1093/cid/cix406 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Flunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses.
Viruses
January 2025
Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
Lassa fever (LF), a viral hemorrhagic fever disease with a case fatality rate that can be over 20% among hospitalized LF patients, is endemic to many West African countries. Currently, no vaccines or therapies are specifically licensed to prevent or treat LF, hence the significance of developing therapeutics against the mammarenavirus Lassa virus (LASV), the causative agent of LF. We used in silico docking approaches to investigate the binding affinities of 2015 existing drugs to LASV proteins known to play critical roles in the formation and activity of the virus ribonucleoprotein complex (vRNP) responsible for directing replication and transcription of the viral genome.
View Article and Find Full Text PDFThe first imported case of Lassa fever in China: a case description.
Quant Imaging Med Surg
January 2025
Department of Radiology, Public Health Clinical Center of Chengdu, Chengdu, China.
[This corrects the article DOI: 10.1371/journal.pone.
View Article and Find Full Text PDFKnowledge, attitude and practice of Lassa fever prevention among adults in Bali Local Government Area, Taraba State, Nigeria.
J Prev Med Hyg
September 2024
College of Medicine Imo State University, Owerri, Imo State, Nigeria.
Introduction: Lassa fever (LF), a public health problem of great importance endemic in West Africa, is an acute and sometimes fatal viral haemorrhagic disease which leads to mortality. The current study assessed the knowledge, attitude and practice of Lassa fever prevention among adults in Bali Local Government Area, Taraba State, Nigeria.
Methods: Descriptive study design and Cross sectional study design was used for this study.
Current perspectives on vaccines and therapeutics for Lassa Fever.
Virol J
December 2024
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!